Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Medgenics — Q3 2016 Earnings Presentation

27 slides from Aevi Genomic Medicine's earnings presentation, Nov 3, 2016

  1. Slide 1: Q3 Business Update and Financials

    Q3 Business Update and Financials November 3, 2016

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financial performance, clinical results,

  3. Slide 3: Q3 2016 Executive Summary

    Q3 2016 Executive Summary 3 NFC – 1 Programs Advancing – mGluR+ ADHD • Enrollment ongoing; top - line data expected around year end • mGluR + prevalence rate of ~25% confirmed • US market opportunity of $ 2B – $3B – 22q Deletion Syndrome • Study initiated at CHOP • Initial data expected in H1 2017 A

  4. Slide 4: Genomic Medicine Approach

    Genomic Medicine Approach medgenics

  5. Slide 5: Genetic Influence in Pediatric Disorders

    Genetic Influence in Pediatric Disorders E arly Onset Disease: Distinct genetically driven Severe burden of illness Aggressive progression Less responsive to standard of care 5 *1Ruel, J. et al. (2013) IBD across the age spectrum — is it the same disease? Nat. Rev. Gastroenterol . Hepatol . doi:10.1

  6. Slide 6: Center for Applied Genomics (CAG) at CHOP

    Center for Applied Genomics (CAG) at CHOP CAG’s pediatric biobank contains a high percentage of rare genetic variants Datasets (Genomics EMR) Over 75K pediatric and 150K related adult patients GWAS genotyped with associated longitudinal EMR since 2006 Data Analytics End to end internal Next - Gen se

  7. Slide 7: CAG/MDGN - Genetic Discoveries to Drugs

    CAG/MDGN - Genetic Discoveries to Drugs 7 Genomically Validated Target Rational Search & Acquisition Genomically Guided Product Development Targeted Launch Medgenics ’ R ole: Match unique genetic discoveries with potential therapies Acquire the rights to programs that have been abandoned – Ideal pro

  8. Slide 8: Benefits of Genomic Guided Drug Development

    Benefits of Genomic Guided Drug Development Higher Value Medicines Improved response rates Smaller, faster, clinical trials Increased probability of regulatory success Targeted launch Potential label expansion in adjacent genetic diseases G enomic biomarkers improve overall program outcomes 8

  9. Slide 9: NFC-1 Program Update

    NFC-1 Program Update medgenics

  10. Slide 10: ADHD: Rationale for Genomic Medicine Approach

    ADHD: Rationale for Genomic Medicine Approach Most prevalent neurodevelopmental disorder in children Highly heritable* (70%); Heterogeneous, suggesting multiple causes Early studies focused on individual genes failed to identify causal associations N ovel discovery from CAG, based on network biology

  11. Slide 11: mGluR Mutations Highly Predictive of ADHD

    mGluR Mutations Highly Predictive of ADHD 11 In a blinded study of 155 mGluR+ patients assessed in CHOP psychiatry > 98% were diagnosed with ADHD H. Hakonarson , data presented at 63rd Annual American Academy of Child and Adolescent Psychiatry in Oct 2016

  12. Slide 12: NFC-1: ADHD Program

    NFC - 1: ADHD Program 12 ADHD Phenotype / Genotype Pediatrics, Adolescents N=1,000+ Design: Non - interventional Multi - center (25) Genotype 1,000+ ADHD subjects, age 6 - 17, identifying patients who are mGluR + Phase 2/3 mGluR+ ADHD, Adolescents N=90, Ages 12 - 17 Phase 3 mGluR+ ADHD, Pediatrics N

  13. Slide 13: Mutation Prevalence Confirmed in Phenotype/Genotype Study

    Mutation Prevalence Confirmed in Phenotype/Genotype Study 13 Data presented at 63 rd Annual American Academy of Child and Adolescent Psychiatry Meetings (AACAP) in Oct 2016 Age Group mGluR+ (n) Total (n) % Pediatrics (ages 6 - 12) 71 271 26% Adolescents (ages 13 - 17) 271 1,274 21% A ddressable pedi

  14. Slide 14: mGluR+ ADHD Patients: Higher Prevalence of Negative Symptoms

    mGluR+ ADHD Patients: Higher Prevalence of Negative Symptoms (n=1013) 14 In mGluR+ patients*: • Symptoms associated with emotional dysregulation most prominent: disruptive behavior, anger control • Emotional dysregulation often has significant life consequences** • Majority of symptoms more prevalen

  15. Slide 15: "Fail First" Treatment Paradigm in ADHD

    • Current diagnostic paradigm is symptom - based without objective biomarkers • Current treatment paradigm exposes children to multiple stimulants in a “fail first” approach • Underlying safety concerns create issues with compliance and adherence: • Cardiovascular risk • Growth retardation • Sleep d

  16. Slide 16: NFC-1: Potential for Superior Product Profile

    NFC - 1: Potential for Superior Product Profile NFC - 1 clinical profile in mGluR+ ADHD patients – Effective non - stimulant (non - scheduled) – Excellent safety profile in >1,000 patients No evidence of growth retardation, addiction, sleep disturbance No evidence of cardiovascular risk No expectati

  17. Slide 17: mGluR+ ADHD: Market Opportunity

    mGluR + ADHD: Market Opportunity Overall US ADHD Market – 2015 Sales in excess of $10B* – ~6M pediatric / adolescent patients** – Stimulants dominate market: 90+% of total prescriptions mGluR + ADHD Market, ages 6 - 17 – 1.2M - 1.5M patients (~25% mGluR+) – $ 2B - $3B market opportunity based upon c

  18. Slide 18: Anti-LIGHT mAb Program

    Anti-LIGHT mAb Program ta medgenics

  19. Slide 19: Anti-LIGHT mAb Program

    Anti - LIGHT mAb Program First - in - Class Biologic from Kyowa Hakko Kirin – Initial development in S evere P ediatric O nset IBD – Phase 2 ready antibody – Strong regulatory e xclusivity and robust i ntellectual p roperty p ortfolio – High value c ommercial o pportunity with potential for indicati

  20. Slide 20: Rationale for Anti-LIGHT Approach

    Rationale for Anti - LIGHT Approach DcR3 is strongly linked to Severe Pediatric Onset IBD 1 Initial strategy to augment DcR3 – Very short half life – Toxicity reported with previous DcR3 analog “Rational Search” based on biological pathway – LIGHT overexpressed in IBD – DcR3 LOF increases LIGHT 2 20

  21. Slide 21: Rapid Development Pathway to Approval

    Rapid Development Pathway to Approval 21 Severe Pediatric Onset IBD POC Trial Anticipated Phase 1b design: Single center (CHOP) N = up to 12 patients Duration 8 weeks Ascending dose Endpoints : Endoscopic Evaluation, Crohn’s Disease Activity Index (CDAI ), Safety Estimated Cost: ~$2M Single Phase 3

  22. Slide 22: Severe Pediatric Onset IBD: Top Down Treatment Paradigm

    Severe Pediatric Onset IBD: “ Top Down” Treatment Paradigm 22 1 Altwegg & Vincent (2014) TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease. Mediators of Inflammation. doi:10.1155/2014/172821 Treatment Objectives : Induce remission with anti - TNFα immediately so

  23. Slide 23: Severe Pediatric Onset IBD: Anti-LIGHT Opportunity

    Severe Pediatric Onset IBD: Anti - LIGHT Opportunity (US Pop.) 23 1 Kappleman et al. (2007) Clin Gastro Hepat 2 Oliva - Hemker (2015) J Pedtr 3 Remicade Monograph 4 Altwegg - Vincent (2014) Mediators of Inflamm Initial Target: anti - TNFα failure with DcR3 Loss of Function 2,000 – 3,000 IBD patients

  24. Slide 24: Financials & Milestones

    Financials & Milestones ta medgenics

  25. Slide 25: Q3 2016 Financial Update

    Q3 2016 Financial Update R&D expenses for the 3 rd Quarter were $7.7M (gross) and $7.5M (net), increasing from $4.6M (gross) and $4.2M (net) for the same period in 2015 – Primarily due to increased spend on clinical activities related to advancing the NFC - 1 (MDGN - 001) program G&A expenses for th

  26. Slide 26: Upcoming Milestones

    Upcoming Milestones 26 R&D Programs Timing NFC - 1 Complete enrollment in phenotype / genotype study ✓ Initiate enrollment in Phase 2/3 mGluR+ ADHD Adolescent Trial ✓ Top line data H2 16 Initiate enrollment in Phase 1/2 22q Deletion Syndrome Trial Q4 16 Initial open - label responder data H1 17 Anti

  27. Slide 27: medgenics

    medgenics

Medgenics — Q3 2016 Earnings Presentation on 6ix